Proportion of responders with Endometriosis Associated Pain assessed using modified Biberoglu and Behrman (B&B) scale Up to Month 3 [clinicaltrials_resource:086eff009f3026eb520390159b0c4b85]

Proportion of responders with Endometriosis Associated Pain assessed using modified Biberoglu and Behrman (B&B) scale Up to Month 3 [clinicaltrials_resource:086eff009f3026eb520390159b0c4b85]

Proportion of responders based on reduction from Baseline
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:086eff009f3026eb520390159b0c4b85
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain [clinicaltrials:NCT01931670]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Proportion of responders with Endometriosis Associated Pain assessed using modified Biberoglu and Behrman (B&B) scale Up to Month 3 [clinicaltrials_resource:086eff009f3026eb520390159b0c4b85]

Proportion of responders based on reduction from Baseline
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:086eff009f3026eb520390159b0c4b85
Bio2RDF identifier
086eff009f3026eb520390159b0c4b85
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:086eff009f3026eb520390159b0c4b85
measure [clinicaltrials_vocabulary:measure]
Proportion of responders with ...... eroglu and Behrman (B&B) scale
time frame [clinicaltrials_vocabulary:time-frame]
description
Proportion of responders based on reduction from Baseline
identifier
clinicaltrials_resource:086eff009f3026eb520390159b0c4b85
title
Proportion of responders with ...... rman (B&B) scale Up to Month 3
@en
inDataset
type
label
Proportion of responders with ...... eff009f3026eb520390159b0c4b85]
@en